Difference between revisions of "Staging page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
−
<span id="BackToTop"></span>
+
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Colorectal_cancer|main colorectal cancer page]] for current regimens.
−
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 
−
[[#top|Back to Top]]
 
−
</div>
 
−
{{#lst:Section editor transclusions|peds}}
 
−
<big>''This page contains studies that were specific to pediatric populations. For the more general ALCL page, follow [[Anaplastic large cell lymphoma|this link]].</big>
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
−
|}
+
|}  
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
=Untreated=
+
=Metastatic disease, first-line=
−
==COG ANHL12P1 protocol {{#subobject:69ug1e|Regimen=1}}==
+
==Fluorouracil & Methotrexate (MF) {{#subobject:bcd024|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Pre-phase {{#subobject:1yxa91|Variant=1}}===
+
===Regimen {{#subobject:909280|Variant=1}}===
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
!style="width: 33%"|Study
+
!style="width: 20%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 20%"|Years of enrollment
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8462406/ Lowe et al. 2021 (COG ANHL12P1)]
+
|[https://www.ejcancer.com/article/S0959-8049(02)00662-7 Wils et al. 2003]
−
|2013-2017
+
|1992-1994
−
| style="background-color:#91cf61" |Randomized Phase 2
+
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[#MF_.26_PALA_77|MF & PALA]]
 +
| style="background-color:#ffffbf" |Seems not superior
 
|-
 
|-
 
|}
 
|}
−
''Note: there appear to be several dosing errors in Table 2; the authors have been contacted for clarification.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
====Glucocorticoid therapy====
 
−
*[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5
 
−
====CNS therapy, prophylaxis====
 
−
*[[Methotrexate (MTX)]] age-based IT once on day 1
 
−
'''5-day course'''
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Induction {{#subobject:1yxa92|Variant=1}}===
 
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
−
====Antibody-drug conjugate therapy====
 
−
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes once on day 1
 
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1
+
*[[Fluorouracil (5-FU)]]
−
*[[Ifosfamide (Ifex)]] as follows:
+
*[[Methotrexate (MTX)]]
−
**Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5
 
−
*[[Etoposide (Vepesid)]] as follows:
 
−
**Cycles 1, 3, 5: 100 mg/m<sup>2</sup> IV once per day on days 4 & 5
 
−
*[[Cytarabine (Ara-C)]] as follows:
 
−
**Cycles 1, 3, 5: 150 mg/m<sup>2</sup> IV every 12 hours on days 4 & 5 (total dose per cycle: 600 mg/m<sup>2</sup>)
 
−
*[[Cyclophosphamide (Cytoxan)]] as follows:
 
−
**Cycles 2, 4, 6: 200 mg/m<sup>2</sup> IV once per day on days 1 to 5
 
−
*[[Doxorubicin (Adriamycin)]] as follows:
 
−
**Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5
 
−
====Glucocorticoid therapy====
 
−
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 1 to 5
 
−
'''21-day cycle for 6 cycles'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''COG ANHL12P1:''' Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021 Jul 1;137(26):3595-3603. [https://doi.org/10.1182/blood.2020009806 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8462406/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33684925/ PubMed] NCT01979536
+
# Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; [[Study_Groups#EORTC|EORTC]] Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. [https://www.ejcancer.com/article/S0959-8049(02)00662-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12565987 PubMed]
−
 
+
==Fluorouracil & Mitomycin {{#subobject:29baf5|Regimen=1}}==
−
==EICNHL ALCL99 protocol {{#subobject:69ug1e|Regimen=1}}==
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Pre-phase {{#subobject:1yxa91|Variant=1}}===
+
===Regimen {{#subobject:e41b97|Variant=1}}===
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
!style="width: 17%"|Study
+
!style="width: 20%"|Study
−
!style="width: 15%"|Years of enrollment
+
!style="width: 20%"|Years of enrollment
−
!style="width: 17%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
!style="width: 17%"|Comparator
+
!style="width: 20%"|Comparator
−
!style="width: 17%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
!style="width: 17%"|[[Levels_of_Evidence#Toxicity|Comparative Toxicity]]
 
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2008.18.1487 Brugières et al. 2009 (EICNHL ALCL99)]
+
|[https://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70094-9/pdf Price et al. 2004]
−
|1999-2005
+
|1996-1998
−
| style="background-color:#1a9851" |Randomized (E-switch-ic)
+
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#EICNHL_ALCL99_protocol|EICHNL ALCL99]]; alternate MTX dosing
+
|[[#Fluorouracil_.26_Mitomycin|Fluorouracil & Mitomycin]]; chronomodulated
−
| style="background-color:#ffffbf" |Inconclusive whether non-inferior EFS
+
| style="background-color:#ffffbf" |Seems not superior
−
| style="background-color:#1a9850" |Less toxic
 
 
|-
 
|-
 
|}
 
|}
−
''Note: the intrathecal component is only described as "triple therapy" in the manuscript.''
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
−
====Glucocorticoid therapy====
 
−
*[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5
 
−
====CNS therapy, prophylaxis====
 
−
*[[Methotrexate (MTX)]] (dose not specified) IT once on day 1
 
−
*[[Cytarabine (Ara-C)]] (dose not specified) IT once on day 1
 
−
*[[Hydrocortisone (Cortef)]] (dose not specified) IT once on day 1
 
−
'''5-day course'''
 
−
</div></div><br>
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Induction {{#subobject:1yjxo1|Variant=1}}===
 
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1
+
*[[Fluorouracil (5-FU)]]
−
*[[Ifosfamide (Ifex)]] as follows:
+
*[[Mitomycin (Mutamycin)]]
−
**Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5
 
−
*[[Etoposide (Vepesid)]] as follows:
 
−
**Cycles 1, 3, 5: 100 mg/m<sup>2</sup> IV once per day on days 4 & 5
 
−
*[[Cytarabine (Ara-C)]] as follows:
 
−
**Cycles 1, 3, 5: 150 mg/m<sup>2</sup> IV every 12 hours on days 4 & 5 (total dose per cycle: 600 mg/m<sup>2</sup>)
 
−
*[[Cyclophosphamide (Cytoxan)]] as follows:
 
−
**Cycles 2, 4, 6: 200 mg/m<sup>2</sup> IV once per day on days 1 to 5
 
−
*[[Doxorubicin (Adriamycin)]] as follows:
 
−
**Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5
 
−
====Glucocorticoid therapy====
 
−
*[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 1 to 5
 
−
'''21-day cycle for 6 cycles'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
#'''EICNHL ALCL99:''' Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009 Feb 20;27(6):897-903. Epub 2009 Jan 12. [https://doi.org/10.1200/jco.2008.18.1487 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19139435/ PubMed] NCT00006455
+
# Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70094-9/pdf link to original article] [https://pubmed.ncbi.nlm.nih.gov/15025796 PubMed]
−
 
+
==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}==
−
==APO{{#subobject:6964de|Regimen=1}}==
 
−
APO: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine)
 
−
HOP: '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 
−
<br>
 
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:985a91|Variant=1}}===
+
===Regimen {{#subobject:4df123|Variant=1}}===
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
!style="width: 33%"|Study
+
!style="width: 20%"|Study
−
!style="width: 33%"|Years of enrollment
+
!style="width: 20%"|Years of enrollment
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682366/ Alexander et al. 2014 (COG ANHL0131)]
+
|[https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S Baker et al. 1976]
−
|2004-2008
+
|1973-1974
−
| style="background-color:#91cf61" |Non-randomized portion of phase 3 RCT
+
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[Colon_cancer#Fluorouracil_monotherapy|5-FU]]
 +
| style="background-color:#1a9850" |Superior ORR
 +
|-
 +
|[https://doi.org/10.1002/1097-0142(19820415)49:8%3C1555::AID-CNCR2820490807%3E3.0.CO;2-C Engstrom et al. 1982 (ECOG E4275)]
 +
|NR
 +
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 +
|1. [[#Fluorouracil.2C_Semustine.2C_Vincristine_99|5-FU, Semustine, Vincristine]]<br>2. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine_99|5-FU, Dacarbazine, Semustine]]<br> 3. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine.2C_Vincristine_99|5-FU, Dacarbazine, Semustine, Vincristine]]<br> 4. [[#Fluorouracil_.26_Hydroxyurea_88|5-FU & Hydrea]]
 +
| style="background-color:#ffffbf" |Seems not superior
 
|-
 
|-
 
|}
 
|}
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once per day on days 1 & 22
+
*[[Fluorouracil (5-FU)]]
−
*[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22, 29
+
*[[Semustine (MeCCNU)]]
−
====Glucocorticoid therapy====
 
−
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup>/day PO on days 1 to 28
 
−
====CNS therapy, prophylaxis====
 
−
*[[Methotrexate (MTX)]] age-adjusted IT once per day on days 1, 8, 22
 
−
'''6-week course'''
 
−
</div>
 
−
<div class="toccolours" style="background-color:#cbd5e7">
 
−
====Subsequent treatment====
 
−
*APO versus APV maintenance
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG ANHL0131:''' Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, Gross TG, Weinstein H. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group. Pediatr Blood Cancer. 2014 Dec;61(12):2236-42. Epub 2014 Aug 23. [https://doi.org/10.1002/pbc.25187 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682366/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25156886 PubMed] NCT00059839
+
# Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. [https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S link to original article] [https://pubmed.ncbi.nlm.nih.gov/779949 PubMed]
−
=Relapsed or refractory, subsequent lines of therapy=
+
# '''ECOG E4275:''' Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. [https://doi.org/10.1002/1097-0142(19820415)49:8%3C1555::AID-CNCR2820490807%3E3.0.CO;2-C link to original article] [https://pubmed.ncbi.nlm.nih.gov/7039814 PubMed]
−
==Crizotinib monotherapy {{#subobject:be5391|Regimen=1}}==
+
==FOLFOX chronotherapy {{#subobject:7239a0|Regimen=1}}==
 +
FOLFOX: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
−
===Regimen {{#subobject:e9c195|Variant=1}}===
+
===Regimen {{#subobject:0af678|Variant=1}}===
−
{| class="wikitable" style="color:white; background-color:#404040"
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
−
|<small>'''FDA-recommended dose'''</small>
+
!style="width: 20%"|Study
−
|-
+
!style="width: 20%"|Years of enrollment
−
|}
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
{| class="wikitable sortable" style="width: 60%; text-align:center;"
+
!style="width: 20%"|Comparator
−
!style="width: 33%"|Study
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
!style="width: 33%"|Years of enrollment
 
−
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730818/ Mossé et al. 2013 (COG ADVL0912)]
+
|[https://doi.org/10.1016/S0140673697033588 Lévi et al. 1997]
−
|2009-2012
+
|1991-1993
−
| style="background-color:#91cf61" |Phase 1/2 (RT)
+
|style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 +
|[[#FOLFOX_88|FOLFOX]]; CI
 +
| style="background-color:#1a9850" |Superior TTF
 
|-
 
|-
 
|}
 
|}
−
''Note: this was an expansion cohort of a phase 1/2 study.''
+
''This schedule is "chronomodulated"; see paper for details.''
−
<div class="toccolours" style="background-color:#fdcdac">
+
====Chemotherapy====
−
====Biomarker eligibility criteria====
+
*[[Folinic acid (Leucovorin)]] 300 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with 5-FU'''
−
*ALK rearrangement
+
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with leucovorin'''
−
</div>
+
*[[Oxaliplatin (Eloxatin)]] 20 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given first'''
−
<div class="toccolours" style="background-color:#b3e2cd">
+
'''21-day cycles'''
−
====Targeted therapy====
 
−
*[[Crizotinib (Xalkori)]] 280 mg/m<sup>2</sup> PO twice per day
 
−
'''28-day cycles'''
 
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''COG ADVL0912:''' Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May;14(6):472-80. Epub 2013 Apr 16. [https://doi.org/10.1016/s1470-2045(13)70095-0 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730818/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23598171 PubMed] NCT00939770
+
# Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. [https://doi.org/10.1016/S0140673697033588 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9291901 PubMed]
−
[[Category:Anaplastic large cell lymphoma regimens]]
+
[[Category:Colorectal cancer regimens]]
 +
[[Category:Historical regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
−
[[Category:T-cell lymphomas]]
+
[[Category:Gastrointestinal cancers]]
−
[[Category:Pediatric hematologic neoplasms]]
 

Revision as of 12:23, 22 October 2022

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main colorectal cancer page for current regimens.

0 regimens on this page
0 variants on this page


Metastatic disease, first-line

Fluorouracil & Methotrexate (MF)

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Wils et al. 2003 1992-1994 Phase 3 (C) MF & PALA Seems not superior

Chemotherapy

References

  1. Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. link to original article PubMed

Fluorouracil & Mitomycin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Price et al. 2004 1996-1998 Phase 3 (C) Fluorouracil & Mitomycin; chronomodulated Seems not superior

Chemotherapy

References

  1. Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. link to original article PubMed

Fluorouracil & Semustine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Baker et al. 1976 1973-1974 Phase 3 (C) 5-FU Superior ORR
Engstrom et al. 1982 (ECOG E4275) NR Phase 3 (E-switch-ic) 1. 5-FU, Semustine, Vincristine
2. 5-FU, Dacarbazine, Semustine
3. 5-FU, Dacarbazine, Semustine, Vincristine
4. 5-FU & Hydrea 		Seems not superior

Chemotherapy

References

  1. Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. link to original article PubMed
  2. ECOG E4275: Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. link to original article PubMed

FOLFOX chronotherapy

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Lévi et al. 1997 1991-1993 Phase 3 (E-switch-ic) FOLFOX; CI Superior TTF

This schedule is "chronomodulated"; see paper for details.

Chemotherapy

21-day cycles

References

  1. Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. link to original article contains dosing details in manuscript PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Staging_page&oldid=63403"